6th India Pharmaceutical Forum 2021



Global Innovation Summit 2021

Indian pharma industry has the potential to grow to USD 120-130 Bn from the current value of USD 44 Bn over the next decade, increasing its contribution to GDP by 100 basis points. One of the key drivers for this growth would be expansion of the industry’s presence in the innovation space which continues to account for 2/3rd of the global pharmaceutical opportunity.

The Global Innovation Summit 2021 aims to bring together key Indian and international stakeholders from the government, industry, academia, investors and researchers to discuss and strategize priorities to foster a thriving innovation ecosystem in the pharmaceuticals industry in India. The key objectives of the Summit are:

– Take stock and discuss recommendations to improve innovation landscape in India
– Share learnings and emerging trends in the global innovation landscape
– Provide platform for entrepreneurs and researchers to showcase their ideas / innovations to support “Discover in India” and enhance access

This summit will serve as the flagship event to build the Indian pharmaceutical industry’s position in R&D and Innovation. Building presence in innovation is now a critical priority for India in order to both address the needs of the healthcare system in the country, as well as globally. India has scientific and technological strength to leverage and move forward in the journey to “Discover in India” from “Make in India”.

Date: 18-19 November 2021

6th Advanced GMP workshop 2021 Date: 20-22 October 2021

A Vision for the Global Generic and Biosimilar Medicines Industry – IGBA Whitepaper Date: 7th July 2021

6th India Pharmaceutical Forum 2021 Date: 24-26 February 2021

Global Innovation Summit 2021 – Agenda

6th Advanced GMP workshop 2021 – Agenda

A Vision for the Global Generic and Biosimilar Medicines Industry – IGBA Whitepaper – Agenda

6th India Pharmaceutical Forum 2021 – Agenda

1st Global Innovation Summit 2021 Date: 18-19 November 2021

Special Address :
Global experience of accelerating innovation

Dr. Martin Lange

Special Address :
Biopharma Innovation at a Global Scale

Mr. Andy Plump

Special Address :
Driving Innovation at Scale: Trends in innovation and best practices from global innovation hubs

Mr. Jake Henry

Special Address :
Roadmap for pharma R&D: Developing an innovation index as a monitoring and evaluation metric

Prof. Arvind Sahay

6th AGMP Workshop Date: 20-22 October 2021

Session 2 :
FDA’s Remote Interactive Evaluations – Expectations and Way Forward

Rachel Harrington

Session 2 :
MHRA Desktop Inspections

Ewan Norton and Ian Jackson

Session 4 :
Testing Methods for N-Nitrosamines Monitoring in Pharmaceuticals

Mrunal Jaywant

Session 4 :
Nitrosamines Impurities – Current Regulatory Status

BM Rao

Session 5 :
Pharmaceutical Advanced Development and Case Analysis​

Prasenjit Dange

Session 6 :
Advanced Manufacturing of Solid Dose Products using ConsiGma 4.0 Continuous Manufacturing solutions

James Holman

Session 6 :
Advancements in Continuous Manufacturing Technology

Niranjan Kottala

Session 7 :
Advancement in Cold Chain Logistics

Dr Ravi Prakash Mathur

Session 7 :
Role of Digital Ledger Technology (DLT) in Next Generation Pharmaceutical Supply Chain

Anubha Dixit

Session 8 :
WHO evaluation stratergy for COVID -19 vaccines

Dr Deus Mubangizi

Session 10 :
Aseptic Practices and correlations with Smoke studies and media fill

Pradipta Swain

Session 10 :
VISUAL INSPECTIONS OF STERILE PRODUCTS

Mustak Sherasia

Session 10 :
Maintenance Practices

Mr. Sanjeev Sharma

Session 10 :
Cleaning Methodology and Validation

Mr Mahendra Singh Charan

6th India Pharmaceutical Forum 2021 Date: 24-26 February 2021

Session 4 :
EDQM Real time remote inspections

Dr Cristina Baccarelli

Session 4 :
Inspection during COVID-19 and overview of GDUFA III negotiations

Mr David Gaugh

Session 4 :
MHRA Remote Inspection Strategies

Ms Paula Walker

Session 6 :
EHS and Sustainability

Mr Koen Laenen

Session 7 :
Global view on regulatory affairs

Dr Rajkiran Jain

Session 7 :
Global view on regulatory affairs

Mr Anthony Lakavage

Session 7 :
Global view on regulatory affairs

Mr K S Babu

Session 7 :
Global view on regulatory affairs

Ms Beata Stepniewska

Session 8 :
Contamination Control

Mr Rajendra Kumar Das

Session 11 :
Future Challenges and Objectives for PDA in AsiaPac

Mr Richard Johnson

Session 11 :
Integrated Risk Management from Design to Delivery

Dr Ghada Haddad

Session 12 :
Quality compliance culture and empowerment in the new normal

Dr Ranjana Pathak

Session 13 :
Panel Discussion – Digitalisation, automation and AI in operations

Ms Geena Malhotra